DAR:NYSEDarling Ingredients Inc. Analysis
Data as of 2026-03-28 - not real-time
$59.28
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Technical outlook remains bullish as the stock trades well above its 20‑day (≈55.5), 50‑day (≈50.7) and 200‑day (≈38.3) moving averages, with a bullish MACD crossover and a strong upward volume trend. However, the RSI of 73 signals an overbought condition and the price is approaching the near‑term resistance around $61.25, suggesting a potential short‑term pullback. Volatility is elevated at roughly 27% over the past 30 days, and beta below 1 indicates modest market sensitivity, but the recent rally of over 5% on high volume underscores momentum.
Fundamental and news drivers show a 20% year‑over‑year revenue growth and improving margins, with Q4 2025 results beating expectations and leverage declining quarter‑over‑quarter. Analysts rate the stock a strong buy with a median price target of $64, implying modest upside (~6%). Yet the DCF fair value of about $17 and a trailing P/E of 152 highlight significant overvaluation, while a high debt‑to‑equity ratio (≈86) and low ROE (~1.5%) raise concerns. Recent positive sentiment is tempered by a downgrade citing geopolitical headwinds, reinforcing a cautious but optimistic stance.
Fundamental and news drivers show a 20% year‑over‑year revenue growth and improving margins, with Q4 2025 results beating expectations and leverage declining quarter‑over‑quarter. Analysts rate the stock a strong buy with a median price target of $64, implying modest upside (~6%). Yet the DCF fair value of about $17 and a trailing P/E of 152 highlight significant overvaluation, while a high debt‑to‑equity ratio (≈86) and low ROE (~1.5%) raise concerns. Recent positive sentiment is tempered by a downgrade citing geopolitical headwinds, reinforcing a cautious but optimistic stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI indicating overbought conditions
- Price near resistance with limited upside
- Strong recent volume but short‑term pullback risk
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Revenue growth above 20% and margin expansion
- Analyst consensus strong‑buy with modest upside to target
- Improving leverage and solid cash flow generation
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Significant overvaluation relative to DCF
- High debt load and low return on equity
- Exposure to regulatory and geopolitical risks in global operations
Key Metrics & Analysis
Financial Health
Revenue Growth20.60%
Profit Margin1.02%
P/E Ratio152.0
ROE1.52%
ROA2.50%
Debt/Equity86.53
P/B Ratio2.0
Op. Cash Flow$1.1B
Free Cash Flow$219.4M
Technical Analysis
TrendBullish
RSI73.3
Support$51.02
Resistance$61.25
MA 20$55.53
MA 50$50.72
MA 200$38.35
MACDBullish
VolumeIncreasing
Fear & Greed Index65.98
Valuation
Fair Value$16.99
Target Price$62.77
Upside/Downside5.89%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.92
Volatility27.16%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.